- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05609994
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (ViCToRy)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is designed to assess the safety and efficacy of the PEPIDH1M vaccine in combination with vorasidenib in adult patients recurrent IDH1 mutant lower grade gliomas. Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Patients will then receive vorasidenib 40 mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid (1 flocculation unit [Lf] in a total volume of 0.4 mL saline). This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib. Notably, a safety lead-in will be performed before commencing on the full study to assess the safety of the combination and evaluation for any dose-limiting toxicity (DLT).
The most common side effects of peptide vaccines are redness or swelling at the injection site, local changes to the texture of skin (hardening) at the injection site, itching, allergic reactions, and a potentially serious side effect called cytokine release syndrome. The most common side effects of vorasidenib are abnormal liver function tests, QT prolongation, stomach and/or intestinal ulcers, neurologic disturbances, skin peeling, and isocitrate dehydrogenase (IDH) differentiation syndrome.
All patients who receive any protocol treatment will be included in either primary or secondary efficacy analyses. Statistical analyses for the primary objective of adverse experience will exclude patients who terminate protocol treatment prematurely (i.e., less than 4 vaccinations) without an unacceptable toxicity.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Katherine Peters, MD, PhD
- Phone Number: 919-684-5301
- Email: dukebrain1@duke.edu
Study Contact Backup
- Name: Stevie Threatt
- Phone Number: 919-684-5301
- Email: dukebrain1@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
Contact:
- Katherine Peters, MD, PhD
- Phone Number: 919-684-5301
- Email: dukebrain1@duke.edu
-
Contact:
- Stevie Threatt
- Phone Number: 919-684-5301
- Email: dukebrain1@duke.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- IDH1R132H expression in primary tumor
- Clinical and/or radiographic, progressive Grade 2-3 glioma with greater than 2 cm of non-enhancing disease in one plane.
- 1st recurrence only
- Signed informed consent
- For females of child-bearing potential, negative serum pregnancy test at screening
- Women of childbearing potential and male participants must agree to practice contraception
- Karnofsky Performance Status (KPS) of ≥ 70
- Expected survival of ≥ 12 months
- Recovered from any clinically relevant toxicities associated with any prior surgery for the treatment of glioma unless stabilized under medical management
Complete Blood Count (CBC)/differential with adequate bone marrow function as defined below within 2 weeks of enrollment:
- Absolute neutrophil count (ANC) ≥ 1000 cells/mm3
- Platelet count ≥ 100,000 cells/mm3
- Hemoglobin (Hgb) ≥ 10 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.)
Adequate renal function as defined below within 2 weeks of enrollment:
- Blood urea nitrogen (BUN) ≤ 25 mg/dl
- Creatinine ≤ 1.7 mg/dl
Adequate hepatic function as defined below within 2 weeks of enrollment:
- Bilirubin ≤ 2.0 mg/dl
- Alanine transaminase (ALT) ≤ 3 x normal range
- Aspartate aminotransferase (AST) ≤ 3 x normal range
Exclusion Criteria:
- Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years (e.g., carcinoma in situ of the breast, oral cavity, and cervix are all permissible)
- Metastases detected below the tentorium or beyond the cranial vault
- More than 1 cm X 1 cm of enhancing disease on gadolinium contrasted MRI imaging
Severe, active co-morbidity, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization
- Myocardial infarction within the last 6 months.
- Known Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition (Note: human immunodeficiency virus [HIV] testing is not required for entry into this protocol. The need to exclude patients with Acquired Immunodeficiency Syndrome (AIDS) from this protocol is necessary because treatments involved in this protocol may be significantly immunosuppressive.)
- Major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy.
- Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study drug
- Patients with a heart-rate corrected QT interval using Fridericia's formula (QTcF) ≥ 450 msec or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome)
- Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Subjects with a sustained viral response to HCV treatment or immunity to prior HBV infection will be permitted (Note: Patients with chronic HBV that is adequately suppressed by institutional practice will be permitted.)
- Patients with active gastrointestinal disease, chronic diarrhea, previous gastric resection or lap band dysphagia, short-gut syndrome, gastroparesis, or other condition that limits the ingestion or gastrointestinal absorption of drugs administered orally (Note: Gastroesophageal reflux disease under medical treatment is allowed.)
- Patient taking any medications that are CYP3A or CYP2C9 substrates with a narrow therapeutic index (Note: Patients should be transferred to other medications before receiving the first dose of study drug.)
- Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the study
- Patients with known hypersensitivity to GM-CSF, yeast-derived products, or any component of Leukine®
- Allergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccine.
- Known hypersensitivity to any component of vorasidenib
- Prior therapy with mIDH1 targeted therapeutics
- Unable to undergo MRI imaging
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PEPIDH1M vaccine + vorasidenib
Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle.
Patients will then receive vorasidenib 40mg orally once a day for 28 days.
After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15.
The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid.
This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area.
Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12.
Patients will receive up to a total of 14 cycles of vorasidenib.
|
Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle.
Patients will then receive vorasidenib 40mg orally once a day for 28 days.
After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15.
The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid.
This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area.
Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12.
Patients will receive up to a total of 14 cycles of vorasidenib.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Describe the efficacy, as measured by progression-free survival (PFS), of the combination of PEPIDH1M vaccine and vorasidenib in adult patients with recurrent IDH1 lower grade glioma
Time Frame: 10 years
|
The time between initiation of cycle 1 vorasidenib and first documentation of disease progression or death
|
10 years
|
To assess the safety of the PEPIDH1M vaccine in combination vorasidenib in adult patients with progressive IDH1 mutant World Health Organization (WHO) Grade 2-3 gliomas
Time Frame: 3.5 years
|
The proportion of patients with an unacceptable toxicity
|
3.5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Katherine Peters, MD, PhD, Duke University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00108636
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Grade Glioma of Brain
-
Neurological Associates of West Los AngelesEnrolling by invitationLow Grade Glioma of BrainUnited States
-
Children's Hospital of PhiladelphiaBlue Earth Diagnostics; Dragon Master FoundationNot yet recruitingGlioma | Low-grade Glioma | Glioma, Malignant | Low Grade Glioma of Brain | Glioma IntracranialUnited States
-
Tilburg UniversityCompletedLow Grade Glioma of Brain | Anaplastic Glioma of BrainNetherlands
-
National Cancer Institute (NCI)RecruitingLow Grade Glioma | Low Grade Astrocytoma | Metastatic Low Grade Astrocytoma | Metastatic Low Grade GliomaUnited States, Canada, Puerto Rico
-
St. Jude Children's Research HospitalSpringWorks Therapeutics, Inc.RecruitingLow-Grade Glioma | Recurrent Low-Grade Glioma | Progressive Low-Grade GliomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 GliomaUnited States, Canada
-
University Hospital, MontpellierNational Development and Research Institutes, Inc.Recruiting
-
Universitaire Ziekenhuizen KU LeuvenCarl Zeiss Meditec AG; ImecRecruiting
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI); American Lebanese Syrian Associated Charities...RecruitingLow Grade Glioma (LGG) of Brain With BRAF Aberration | High Grade Glioma (HGG) of the Brain With BRAF Aberration | Low Grade Glioma of Brain With Neurofibromatosis Type 1United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGlioblastoma | Malignant Glioma | WHO Grade III Glioma | Metastatic Malignant Neoplasm in the Brain | Low Grade Glioma | PartnerUnited States
Clinical Trials on PEPIDH1M vaccine + vorasidenib
-
ServierServier Pharmaceuticals, LLCAvailablePathologic Processes | Glioma | Neoplasms | Neoplasms by Histologic Type | Neoplasms, Glandular and Epithelial | Recurrence | Disease Attributes | Neoplasms, Germ Cell and Embryonal | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Neoplasms, Nerve Tissue
-
Institut de Recherches Internationales ServierCompleted
-
Institut de Recherches Internationales ServierActive, not recruitingRecurrent Glioma | Grade 2 Glioma | Residual GliomaUnited States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
-
Agios Pharmaceuticals, Inc.CompletedHealthy VolunteersUnited States
-
Indiana Nanotech, LLCThe University of Texas Health Science Center at San AntonioCompleted
-
Katy Peters, MD, PhDCompletedBrain Cancer | Brain Tumor | Brain Neoplasm, Primary | Brain Neoplasms, Recurrent | Cancer of the BrainUnited States
-
Galmed Medical ReserchHillel Yaffe Medical Center; Hadassah Medical Organization; Tel-Aviv Sourasky... and other collaboratorsCompletedStudy of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis (Aramchol003)Metabolic Syndrome | Nonalcoholic Steatohepatitis | Non-Alcoholic Fatty Liver DiseaseIsrael
-
Institut de Recherches Internationales ServierNot yet recruitingIDH1-mutant Glioma | IDH2-mutant Glioma
-
Servier Bio-Innovation LLCInstitut de Recherches Internationales ServierRecruiting
-
Institut de Recherches Internationales ServierMerck Sharp & Dohme LLCRecruiting